Significance: VEGF is the pivotal growth factor for angiogenesis, and its inhibition by passive immunotherapy results in improved survival in patients with several types of cancer. We believe that the clinical benefit could be increased by inducing a humoral immune response against VEGF through active immunization with VEGF-based peptides. In this study, we describe that correct peptide design is vital for success. We show that only 3D-structured peptides perfectly mimicking the crucial β5–turn–β6 loop of endogenous VEGF are able to induce neutralizing antibodies. We developed a vaccine with potent in vitro and in vivo VEGF-neutralizing activities, as shown in passive and active immunization tumor models. The VEGF vaccination strategy has the potential to outperform current clinical anti-VEGF treatment strategies.
11 April 2017 in Proceedings of the National Academy of Sciences
We read with great interest the letter by Marchiò et al. (1) on our recently published paper describing the rational design and testing of a vaccine directed against the major angiogenic growth factor VEGF (2). The letter raises the concern that the potential of the vaccine is limited because of the anaphylactic responses observed in the active vaccination experiments in mice and the incomplete tumor responses observed. The adverse effects observed were most likely because of the high antigen dose (10 mg/kg per immunization) used in the mouse studies. Rats treated with much lower doses (0.5 mg/kg per immunization) lacked such adverse responses. Similarly, extensive studies in cynomolgus monkeys demonstrated the …